36016-97-4

Basic information

• Product Name: 2-(acetylamino)-1,3-thiazol-5-yl thiocyanate
• CAS NO: 36016-97-4
• Molecular Formula: C₆H₅N₃OS₂
• Molecular Weight: 199.2534
• Mol File: 36016-97-4.mol
• Article Data: 5

Chemical Properties

• Density: 1.47g/cm³
• Refractive Index: 1.636
• CAS DataBase Reference: 2-(acetylamino)-1,3-thiazol-5-yl thiocyanate(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(acetylamino)-1,3-thiazol-5-yl thiocyanate(36016-97-4)
• EPA Substance Registry System: 2-(acetylamino)-1,3-thiazol-5-yl thiocyanate(36016-97-4)

Safety Data

• Hazardous Substances Data: 36016-97-4(Hazardous Substances Data)

Upstream product

• 540-72-7 sodium thiocyanide 
• 2719-23-5 2-acetamidothiazole 
• 333-20-0 potassium thioacyanate 
• 23056-10-2 2-amino-5-thiocyanatothiazole 
• 108-24-7 acetic anhydride 
• 1147550-11-5 ammonium thiocyanate 

Downstream Products

• 99171-11-6 5-(methylsulfanyl)-1,3-thiazol-2-amine 

Relevant articles and documents

PIPERIDINE OR PIPERAZINE LINKED IMIDAZOLE AND TRIAZOLE DERIVATIVES AND METHODS OF USE THEREOF FOR IMPROVING THE PHARMACOKINETICS OF A DRUG

The present invention relates to piperidine or piperazine linked imidazole and triazole derivatives, compositions comprising said compounds, alone or in combination with other drugs, and methods of using the compounds for improving the pharmacokinetics of a drug. The compounds of the invention are useful in human and veterinary medicine for inhbiting CYP3A4 and for improving the pharmacokinetics of a therapeutic compound that is metabolized by CYP3A4.

Discovery of aminothiazole inhibitors of cyclin-dependent kinase 2: Synthesis, x-ray crystallographic analysis, and biological activities

High throughput screening identified 2-acetamido-thiazolylthio acetic ester 1 as an inhibitor of cyclin-dependent kinase 2 (CDK2). Because this compound is inactive in cells and unstable in plasma, we have stabilized it to metabolic hydrolysis by replacing the ester moiety with a 5-ethyl-substituted oxazole as in compound 14. Combinatorial and parallel synthesis provided a rapid analysis of the structure-activity relationship (SAR) for these inhibitors of CDK2, and over 100 analogues with IC50 values in the 1-10 nM range were rapidly prepared. The X-ray crystallographic data of the inhibitors bound to the active site of CDK2 protein provided insight into the binding modes of these inhibitors, and the SAR of this series of analogues was rationalized. Many of these analogues displayed potent and broad spectrum antiproliferative activity across a panel of tumor cell lines in vitro. In addition, A2780 ovarian carcinoma cells undergo rapid apoptosis following exposure to CDK2 inhibitors of this class. Mechanism of action studies have confirmed that the phosphorylation of CDK2 substrates such as RB, histone H1, and DNA polymerase α (p70 subunit) is reduced in the presence of compound 14. Further optimization led to compounds such as water soluble 45, which possesses a favorable pharmacokinetic profile in mice and demonstrates significant antitumor activity in vivo in several murine and human models, including an engineered murine mammary tumor that overexpresses cyclin E, the coactivator of CDK2.

Aminothiazole inhibitors of cyclin dependent kinases

Compounds of the formula and pharmaceuticaly acceptable salts thereof. As used in formula I, and throughout the specification, the symbols have the following meanings: R1 and R2 are independently hydrogen, fluorine or alkyl; R3 is aryl or heteroaryl R4 is